Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
BriaCell Therapeutics Corp (BCTXW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: BCTXW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -85.19% | Avg. Invested days 16 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 48.08M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 1.72 | 52 Weeks Range 0.02 - 0.70 | Updated Date 06/18/2025 |
52 Weeks Range 0.02 - 0.70 | Updated Date 06/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -131.54% | Return on Equity (TTM) -688.17% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 5776754 |
Shares Outstanding - | Shares Floating 5776754 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
BriaCell Therapeutics Corp
Company Overview
History and Background
BriaCell Therapeutics Corp. is a biotechnology company focused on developing targeted immunotherapies for cancer. Founded in 2011, it aims to improve outcomes for patients with advanced cancers. The company has achieved milestones in developing its lead candidate, Bria-IMTu2122.
Core Business Areas
- Oncology Immunotherapy: BriaCell focuses on developing immunotherapies to treat advanced cancers, primarily breast cancer.
Leadership and Structure
Dr. William V. Williams serves as President & CEO. The company has a board of directors overseeing strategy and governance.
Top Products and Market Share
Key Offerings
- Bria-IMTu2122: Bria-IMTu2122 is BriaCell's lead immunotherapy candidate for advanced breast cancer. Market share data is currently not applicable as the product is still in clinical development. Competitors include established pharmaceutical companies developing similar immunotherapies. Some of the major competitors in the oncology space include Roche (RHHBY), Novartis (NVS), and Merck (MRK).
Market Dynamics
Industry Overview
The oncology immunotherapy market is experiencing significant growth, driven by advances in understanding the immune system's role in fighting cancer. There is strong demand for new and effective treatments for advanced cancers.
Positioning
BriaCell is a smaller player focused on developing novel immunotherapies. Its competitive advantage lies in its unique approach to personalized immunotherapy.
Total Addressable Market (TAM)
The total addressable market for cancer immunotherapies is substantial, projected to reach billions of dollars annually. BriaCell is positioned to capture a share of this market if Bria-IMT is approved.
Upturn SWOT Analysis
Strengths
- Novel immunotherapy approach
- Targeted therapies for specific cancer types
- Experienced leadership team
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on clinical trial outcomes
- Lack of established commercial infrastructure
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline to other cancer types
- Positive clinical trial results
Threats
- Regulatory hurdles
- Competition from established therapies
- Clinical trial failures
Competitors and Market Share
Key Competitors
- MRK
- BMY
- PFE
- AZN
- RHHBY
Competitive Landscape
BriaCell faces intense competition from larger pharmaceutical companies with significantly greater resources. Its advantage lies in its novel technology and focus on personalized immunotherapy.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by progress in clinical trials and development of Bria-IMT.
Future Projections: Future growth is heavily dependent on successful clinical trial outcomes and regulatory approvals. Analyst estimates vary widely due to the inherent uncertainty in biotechnology development.
Recent Initiatives: Recent initiatives include advancing clinical trials for Bria-IMT and exploring partnerships to expand the pipeline.
Summary
BriaCell is a high-risk, high-reward biotechnology company. Its success hinges on the clinical development of Bria-IMT. The company needs to manage its cash flow carefully and secure partnerships to advance its pipeline. Positive clinical trial results are essential for its long-term viability.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company press releases
- SEC filings
- Market research reports
- Analyst reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investing in biotechnology companies is highly speculative and involves significant risks. Market share data are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BriaCell Therapeutics Corp
Exchange NASDAQ | Headquaters West Vancouver, BC, Canada | ||
IPO Launch date 2021-02-24 | CEO, President & Director Dr. William V. Williams FCPA, M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://briacell.com |
Full time employees - | Website https://briacell.com | ||
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.